RETA - Rasio rega marang prakiraan pendapatan Reata Pharmaceuticals, Inc.

Reata Pharma (RETA) - logo korporat

Developing drugs for rare pathologies requires colossal expenditures and FDA approval, which is reflected in the forward P/S ratio. The growth of this metric is driven by the implementation of IT platforms for analyzing brain degeneration, while the 233.60 level records fresh values. Current price action is explained by the acquisition of Reata Pharmaceuticals (RETA) by an industry leader to facilitate the global market launch of the breakthrough drug Skyclarys.

Reata Pharmaceuticals Inc - Prakiraan rega marang pendapatan RETA (periode 04.07.2022 - 07.10.2023)

Rincian metrik komprehensif lan analitis Reata Pharma (RETA)

- rega pasar lan target rega analis:
Bagan rega Reata Pharmaceuticals, Inc.|RETA - Bagan rega target
- statistik kapitalisasi pasar:
Nilai pasar Reata Pharma|RETA - Total Nilai Perusahaan
- indikator nilai buku ekuitas:
Nilai Buku saben Saham Reata Pharmaceuticals|RETA - Nilai Buku Bisnis|Rasio Kapitalisasi marang Aset Bersih reatapharma.com|RETA - Aset Perusahaan
- data utang lan likuiditas:
Utang marang Ekuitas Reata Pharmaceuticals|RETA - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang modal Reata Pharmaceuticals|RETA - Utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku Reata Pharma|RETA - Utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Reata Pharmaceuticals|Rasio cepet reatapharma.com
- rincian asil keuangan lan kelipatan valuasi:
RETA - Bathi resik|Bathi mangsa ngarep Reata Pharmaceuticals|RETA - Nilai perusahaan marang bathi resik|Rega marang bathi mangsa ngarep Reata|RETA - Rasio kapitalisasi marang bathi lan wutah|Pangali EV/EBITDA Reata Pharma|RETA - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) Reata Pharmaceuticals|RETA - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan reatapharma.com|RETA - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Reata Pharmaceuticals
- data pendapatan lan penerimaan dodolan:
RETA - Dodolan perusahaan|Prakiraan volume dodolan Reata Pharmaceuticals, Inc.|RETA - Multiplikator P/S|Multiplikator Forward P/S Reata Pharma
Analisis wiwitan perusahaan:Reata Pharmaceuticals, Inc. RETA
Produk asli Reata Pharma

The forward P/S ratio assesses the market value of the business relative to expected revenue, revealing the impact of cost inflation and pressure on operating margins during periods of market volatility. For Reata Pharmaceuticals (RETA), this chart's trend confirms capitalization resilience driven by the indispensable demand for Skyclarys, which serves as a steady cash generator and offsets the risks of an operational downturn.

Pesaing Reata Pharmaceuticals

Rasio rega marang prakiraan pendapatan Jazz Pharmaceuticals plc JAZZ|Cytokinetics Inc. - Rasio rega marang prakiraan pendapatan|PTCT - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Scholar Rock Inc.|CNTA: Multiplikator Forward P/S|Prakiraan rega marang pendapatan dyne-tx.com DYN|Multiplikator forward rega marang pendapatan EWTX|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Rapport Therapeutics Inc RAPP|Rasio rega marang prakiraan pendapatan Alumis Corp (ALMS)|ZVRA (Zevra Corp) - Rega forward marang dodolan|Multiplikator Forward P/S CTNM (Contineum Therapeutics, Inc.)|larimartx.com (LRMR) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Capricor - Multiplikator Forward P/S|TRDA - Multiplikator Forward P/S|PTHS (Channel) - Multiplikator forward rega marang pendapatan|MNOV: Rasio rega marang pendapatan sing dikarepake|SER (Serina Therapeutics, Inc.) - Multiplikator Forward P/S|Multiplikator Forward P/S bioxceltherapeutics.com|Multiplikator forward rega marang pendapatan PMN (ProMIS Neurosciences)|APUS (apimedsus.com) - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan AEON Biopharma, Inc. AEON|NLSP (NLS Pharmaceutics Ltd.) - Rega mangsa ngarep marang pendapatan|Bionomics Ltd - Multiplikator Forward P/S|Rega forward marang dodolan HUGE (FSD Pharma, Inc.)